Shares of clinical-stage biopharmaceutical company ABVC BioPharma (NASDAQ:ABVC) are in focus today after its Phase 2 part 2 study of ADHD candidate ABV-1505 enrolled a total of 30 patients.
The drug is being developed for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and is anticipated to enroll a total of 100 patients in Taiwan and the U.S.
Moreover, the University of California, San Francisco (UCSF) has approved participation in this study. Part 1 of the study was conducted at UCSF as well.
Read full Disclosure
